Camp4 Therapeutics Corporation (CAMP)
| Market Cap | 263.57M +32.3% |
| Revenue (ttm) | 5.32M +39.9% |
| Net Income | -121.10M |
| EPS | -1.95 |
| Shares Out | 62.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,222 |
| Open | 4.410 |
| Previous Close | 4.330 |
| Day's Range | 4.130 - 4.415 |
| 52-Week Range | 2.900 - 7.750 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | 10.22 (+143.33%) |
| Earnings Date | Nov 5, 2026 |
About CAMP
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015... [Read more]
Financial Performance
In 2025, Camp4 Therapeutics's revenue was $3.50 million, an increase of 436.50% compared to the previous year's $652,000. Losses were -$80.40 million, 55.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CAMP stock is "Strong Buy." The 12-month stock price target is $10.22, which is an increase of 143.33% from the latest price.
News
Camp4 Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
The platform uses ASOs to raise target gene expression, with SYNGAP clinical data guided for H1 2028. SHANK3 is advancing toward a 2027 development-candidate goal, alongside plans for further collaborations.
Camp4 Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
The SYNGAP1 Phase I/II trial is advancing toward first dosing by year-end 2026, with initial data targeted for H1 2028. The platform’s next CNS program is SHANK3, while cash runway extends through end-2028.
Camp4 Therapeutics reports Q3 EPS (37c), consensus (22c)
Reports Q3 revenue $1.9M, consensus $1.72M. “The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the…
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearanc...
Camp4 Therapeutics Quarterly report: Q3 2026
Camp4 Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Camp4 Therapeutics Earnings release: Q3 2026
Camp4 Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Camp4 Therapeutics receives CTA approval for CMP-002 in the European Union
CAMP4 Therapeutics (CAMP) announced that it has received clinical trial application, or CTA, approval from the regulatory authorities and ethics committees of multiple EU countries to initiate the com...
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
Camp4 Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Camp4 Therapeutics (CAMP) with a Strong Buy rating and $10 price target CMP-002 represents an underappreciated, potentially multibillion-dollar opportunity in SYNGA...
Camp4 Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
Korro is advancing pan-UCD candidate KRRO-121, with patient dosing targeted for H1 2027 and data for H2 2027. Tevard reported preclinical protein rescue and aims for clinical entry by late 2027 or early 2028.
Camp4 Therapeutics initiated with a Buy at Needham
Needham initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $8 price target The company’s lead asset CMP-002 is an antisense oligonucleotide in Phase 1/2 development for SYNGAP1-rela...
CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin...
Camp4 Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $15 price target. The firm believes Camp4’s $190M EV discounts strategic interest in developmental/epileptic e...
Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $6 from $6.50 and keeps a Buy rating on the shares following the company’s analyst event.
Camp4 Therapeutics Transcript: Analyst Day 2026
CMP-002 is advancing in a global phase I/II trial for SYNGAP1, targeting multiple domains such as seizures, sleep, and cognition, with top-line results expected in 2028. The platform's success in preclinical models supports expansion to SHANK3 and other haploinsufficiency disorders, with robust patient and regulatory engagement guiding development.
Camp4 Therapeutics Slides: FY 2026
Camp4 Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 28, 2026.
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
Camp4 Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
SYNGAP1, a rare neurological disorder with no approved therapies, is the focus of an upcoming phase I trial authorized in multiple countries and set to begin in Q4. The multi-cohort study uses preclinical and natural history data, with endpoints in cognitive, motor, and seizure domains. Analyst Day will provide further trial and pipeline updates.
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeti...
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c)
Reports Q2 revenue $1.78M, consensus $1.89M. “Having secured regulatory clearance in both Australia and Argentina, we are now focused on initiating our first-in-human Phase 1/2 clinical trial of CMP-0...
Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on Camp4 Therapeutics (CAMP) to $15 from $12 and keeps an Overweight rating on the shares. The firm notes Camp4 ended Q2 with…
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ...
Camp4 Therapeutics Quarterly report: Q2 2026
Camp4 Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Camp4 Therapeutics Earnings release: Q2 2026
Camp4 Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.